My ePortfolio Register   

WIN Symposium 2017 /
Incorporating liquid biopsies into clinical trials

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 549

Dr Daniel Hayes - University of Michigan Comprehensive Cancer Center, Ann Arbor, USA

Dr Hayes speaks with ecancer at WIN 2017 about ease of use and wealth of information made possible with liquid biopsy to derive tumour genomics.

He describes the utility of serial biopsies in guiding patients selection of treatment or trial participation, and also how interrogation of this data may determine suitable biomarkers for further research, or reveal the development of resistance pathways in real time.

Dr Hayes considers the use of circulating biomarkers as surrogates for clinical endpoints, and contemplates the historic context of personalised therapy from the first vaccines to the current understandings of tumour heterogeneity.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence